Plain-English translation of NCT05320835 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This is a pilot study testing whether peer education—where people who inject drugs are trained to teach their friends and community about safer injection practices—can help reduce the spread of HIV and hepatitis C, as well as overdose risk. The study focuses on Baltimore and involves training 120 community members to provide education and distribute harm-reduction supplies (like clean needles and overdose reversal medication) in places where people gather to inject drugs. The hope is that conversations between peers will help shift attitudes about safety and encourage people to use these protective resources.
People who inject drugs face serious risks from HIV, hepatitis C, and overdose, and traditional public health messages don't always reach them effectively. This study explores whether relying on trusted peers—rather than outside health workers—to share harm-reduction information and supplies can be more effective and empowering for the community.
You likely qualify if…
You likely don't qualify if…
If you are selected as an 'index' participant, you will receive six training sessions focused on how to talk with others about safer injection practices, HIV and hepatitis C prevention, and overdose prevention. You'll learn how to share harm-reduction supplies (like clean needles and naloxone, a life-saving overdose reversal medication) in semi-public spaces where people in your community gather. The study team will then track whether your peer education efforts and the availability of these supplies lead to safer behaviors among people you interact with.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States
Sponsor
Johns Hopkins Bloomberg School of Public Health
Collaborators
National Institute on Drug Abuse (NIDA)
Enrollment target
~285 participants
Started
April 2022
Primary completion
December 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Carl Latkin, PhD
Johns Hopkins Bloomberg School of Public Health
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.